Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 16
Results: 10
1
2
Correction to: Rozanolixizumab: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
3
Pozelimab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1551, doi. 10.1007/s40265-023-01955-9
- By:
- Publication type:
- Article
4
Zuranolone: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1559, doi. 10.1007/s40265-023-01953-x
- By:
- Publication type:
- Article
5
Tafolecimab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1545, doi. 10.1007/s40265-023-01952-y
- By:
- Publication type:
- Article
6
Lotilaner Ophthalmic Solution 0.25%: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1537, doi. 10.1007/s40265-023-01947-9
- By:
- Publication type:
- Article
7
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1501, doi. 10.1007/s40265-023-01944-y
- By:
- Publication type:
- Article
8
Continued Opioid Use and Adverse Events Following Provision of Opioids for Musculoskeletal Pain in the Emergency Department: A Systematic Review and Meta-Analysis.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1523, doi. 10.1007/s40265-023-01941-1
- By:
- Publication type:
- Article
9
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1475, doi. 10.1007/s40265-023-01940-2
- By:
- Publication type:
- Article
10
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1459, doi. 10.1007/s40265-023-01939-9
- By:
- Publication type:
- Article